Signal Capital Names Biotech. Expert Vice Chairman

Jul 31 2009 | 9:46am ET

Alternative investments firm Signal Capital Management has named a biotech expert as executive and academic vice chairman.

Roger van Hanwehr is CEO of energy technology development company Solus and co-founder of consulting firm Arcxeon. He also teaches biotechnology at Georgetown University in Washington, D.C.

Hanwehr, a polymath with expertise in such diverse fields as biological and radiological defense, renewable energy and nanotechnology, will evaluate investment opportunities in his new role at Signal.


In Depth

Steinbrugge: Top 10 Hedge Fund Industry Trends for 2017

Jan 3 2017 | 9:03pm ET

Each year, Agecroft Partners' Don Steinbrugge predicts the top hedge fund industry...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

DarcMatter: The Top Trends in Alternative Investments for 2017

Jan 13 2017 | 8:22pm ET

The $7 trillion alternative investments industry is poised for continued growth...

 

From the current issue of

Securities and Exchange Commission Chair Mary Jo White will step down as chair of the nation’s Wall Street overseer in January, setting the stage for a potential conservative shift in the regulator’s leadership under the incoming Donald Trump administration.